Tozzi V, Galgani S, Gerace C, Narciso P, Balestra P, Sette P, Meccia A, Pau F, Visco G; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 184 (abstract no. M.B.2011).

USL RM10: L. Spallanzani Hosp., Rome, Italy

OBJECTIVE: To assess long term efficacy and tolerance of Zidovudine (AZT) therapy for AIDS dementia complex (ADC). METHODS: 30 patients (pts) with ADC (11 stage 1, 6 st.2, 9 st.3, 4 st.4 according to Price) were treated with AZT at daily doses of 1.000mg (9pts), 750mg (8pts) and 500mg (13pts). Subjects with present or past opportunistic infections or tumors of the CNS were excluded. Pts were followed up for 12 months with neurological examination, neuropsychological evaluations and in some cases MRI and SPECT studies. Modifications of ADC staging and of neuropsychological evaluations were used as outcome criteria. RESULTS: Improvement of neurologic disfunctions was observed as shown: TABULAR DATA, SEE ABSTRACT VOLUME. Complete or partial reversal of MRI and SPECT abnormalities was observed in 9/13 and in 12/14 pts respectively, sometimes in correlation with clinical response. CONCLUSIONS: AZT may reduce the severity of ADC. However the benefit is often only transient with several relapses occurring after 12 months especially in stage 3 and 4 pts.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Dementia Complex
• Biomedical Research
• Humans
• Magnetic Resonance Imaging
• Tomography, Emission-Computed, Single-Photon
• Zidovudine
• radionuclide imaging
• therapy

Other ID:

• 1201191

UI: 102182935

From Meeting Abstracts